OBJECTIVETo investigate the effect of verapamil on the pharmacokinetics of puerarin in rats.

METHODPuerarin with or without verapamil was administered intravenously or orally to rats. The concentration of puerarin in serum was determined by HPLC.

RESULTNo significant difference was found between the control and 0.5 microg x g(-1) verapamil combined groups for intravenous administration, and there was significant difference between the control and 2. 5 microg x g(-1) verapamil combined groups (P < 0.05). When puerarin was administered orally with verapamil, significant difference was found between the control and combined groups (P < 0.05).

CONCLUSIONVerapamil inhibited puerarin metabolism when puerarin was coadministered with verapamil, so it is necessary to change the therapeutic dose of puerarin.

Administration, Oral ; Animals ; Chromatography, High Pressure Liquid ; Drug Interactions ; Isoflavones ; administration & dosage ; blood ; pharmacokinetics ; Male ; Rats ; Vasodilator Agents ; pharmacokinetics ; pharmacology ; Verapamil ; pharmacology

Paclitaxel (PTX) is one of the most frequently used anticancer agent for treating refractory ovarian cancer, metastatic breast cancer and non-small cell lung cancer. However, its oral administration is impeded by very low bioavailability (<5%) due to the P-glycopprotein (P-gp) efflux pump effect. This study investigated in vitro and in vivo P-gp inhibitory effects of adamantyl derivatives AC-603 and AC-786 in rats. Two adamantyl derivatives tested in this study increased the cytotoxicity of daunomycin (DNM) in P-gp overexpressed cell line by inhibiting P-gp efflux function. Pharmacokinetics of PTX with orally co-administered P-gp inhibitors were assessed in rats to improve PTX absorption. The pharmacokinetic parameters of PTX were determined in rats after intravenous (2 mg/kg) or oral (25 mg/kg) administration in the presence or absence of verapamil (a positive control), AC-603 or AC-786 (0.5 mg/kg or 5 mg/kg). Compared to control group (PTX alone), experimental groups (PTX with AC-603 or AC-786) significantly increased the area under the plasma concentration-time curve of PTX following oral administration by 1.7–2.2 fold. The volume of distribution and total clearance of PTX were decreased, while other parameters were not significantly changed. In conclusion, co-administration of AC-603 or AC-786 enhanced the relative bioavailability of orally administered PTX as compared to control.
Absorption ; Administration, Oral ; Animals ; Biological Availability ; Breast Neoplasms ; Carcinoma, Non-Small-Cell Lung ; Cell Line ; Daunorubicin ; In Vitro Techniques ; Ovarian Neoplasms ; P-Glycoprotein ; Paclitaxel* ; Pharmacokinetics ; Plasma ; Rats* ; Verapamil

This study aimed to investigate the in vivo relevance of P-glycoprotein (P-gp) in the pharmacokinetics and adverse effect of phenformin. To investigate the involvement of P-gp in the transport of phenformin, a bi-directional transport of phenformin was carried out in LLC-PK1 cells overexpressing P-gp, LLC-PK1-Pgp. Basal to apical transport of phenformin was 3.9-fold greater than apical to basal transport and became saturated with increasing phenformin concentration (2-75 µM) in LLC-PK1-Pgp, suggesting the involvement of P-gp in phenformin transport. Intrinsic clearance mediated by P-gp was 1.9 µL/min while passive diffusion clearance was 0.31 µL/min. Thus, P-gp contributed more to phenformin transport than passive diffusion. To investigate the contribution of P-gp on the pharmacokinetics and adverse effect of phenformin, the effects of verapamil, a P-gp inhibitor, on the pharmacokinetics of phenformin were also examined in rats. The plasma concentrations of phenformin were increased following oral administration of phenformin and intravenous verapamil infusion compared with those administerd phenformin alone. Pharmacokinetic parameters such as Cmax and AUC of phenformin increased and CL/F and Vss/F decreased as a consequence of verapamil treatment. These results suggested that P-gp blockade by verapamil may decrease the phenformin disposition and increase plasma phenformin concentrations. P-gp inhibition by verapamil treatment also increased plasma lactate concentration, which is a crucial adverse event of phenformin. In conclusion, P-gp may play an important role in phenformin transport process and, therefore, contribute to the modulation of pharmacokinetics of phenformin and onset of plasma lactate level.
Administration, Oral ; Animals ; Area Under Curve ; Diffusion ; Intestinal Absorption ; Lactic Acid* ; LLC-PK1 Cells ; P-Glycoprotein* ; Pharmacokinetics ; Phenformin* ; Plasma* ; Rats ; Swine ; Verapamil

OBJECTIVETo evaluate the effect of Radix euphorbiae pekinensis extract on the permeability and bioavailability of paclitaxel co-administered orally.

METHODSBased on Ussing Chamber and in vivo experiment, the permeability and bioavailability of paclitaxel were evaluated after oral co-administration with radix euphorbiae pekinensis in rats. The contents of paclitaxel in the permeates and the blood samples were determined using HPLC and LC-MS/MS method, respectively.

RESULTSIn Radix euphorbiae pekinensis co-administration group, the Papp of the mucosal-to-serosal (M-S) transport or serosal-to-mucosal transport (S-M) of paclitaxel in the jejunum or ileum segment differed significantly from those in verapamil co-administration group and blank control group (P<0.05), but the Papp of S-M transport in the colon showed no significant difference from that in the blank control group. In the blank group, the average absolute bioavailability (AB%) of orally administered paclitaxel was only 2.81%, compared to that of 7.63% in radix euphorbiae pekinensis group. The average AB% in verapamil group was about 1.5 times that of the blank group.

CONCLUSIONCo-administration of Radix euphorbiae pekinensis extract can increase the bioavailability of orally administered paclitaxel.

Administration, Oral ; Animals ; Biological Availability ; Biological Transport ; Chromatography, High Pressure Liquid ; Euphorbiaceae ; chemistry ; Paclitaxel ; pharmacokinetics ; Permeability ; Plant Extracts ; pharmacology ; Plant Roots ; chemistry ; Rats ; Tandem Mass Spectrometry ; Verapamil

To prepare verapamil hydrochloride (VH) core-in-cup tablets with tri-layered tablet and four-layered tablet as core tablets, separately, which can provide biphasic release with double-pulsatile and multi-phasic release, core tablets were prepared by direct compression method, and core-in-cup tablets by dry-compression coated technology. The parameter, time-lag (T(lag)), was used to evaluate the influence of factors, such as the weight of the top cover layer, the amount of hydroxypropylmethylcellulose (HPMC), and the compression load on VH release. With the increase of the weight and HPMC amount of the top cover layer, the first lag time T(lag1) was prolonged. The second lag time T(lag2) of core-in-cup tablet with four-layered tablet as core tablet increased with the increasing amount of HPMC K100M. With the increase of compression load among the range (6 - 10 kg x cm(-2)), the two lag times were prolonged. Core-in-cup tablets with double-pulsatile and multi-phasic release released VH after the first lag time (4 -5 h), then kept sustained release for 12 h or 13 h, finally released rapidly. The drug in the core-in-cup tablet only released from the top cover layer. T(lag) is determined by the erosion rate of the inhibitor layers (the top cover layer and the sustained-release layer of the multi-layer core tablet).
Delayed-Action Preparations ; Drug Carriers ; Drug Compounding ; methods ; Drug Delivery Systems ; Excipients ; chemistry ; Hypromellose Derivatives ; Methylcellulose ; analogs & derivatives ; chemistry ; Tablets ; Verapamil ; administration & dosage

AIMTo prepare verapamil hydrochloride controlled-onset extended-release pellets (VH-COERP) and study its release behavior in vitro. To compare the pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of VH-COERP and verapamil hydrochloride delayed-release pellets (VH-DRP) as reference.

METHODSThe core of VH-COERP were prepared in the fluidized bed (mini-glatt) by spraying water solution containing drugs onto sucrose-starch pellets with hydroroxy propyl methyl cellulose (HPMC) as the inner coating swelling layer and ethylcellulouse aqueous dispersion as the outer coating controlled layer. Through modifying the coating level of inner and outer layer, the VH-COERP with the optimized cumulative release profile was obtained. The concentration of VH in plasma of six dogs and its pharmacokinetic behaviors after oral administration of VH-COERP and VH-DRP at different times were studied by RP-HPLC. The pharmacokinetic parameters were computed by software program 3P97.

RESULTSThe lag time, the release behavior and the amount of VH from VH-COERP within 24 hours were not influenced by the pH of dissolution medium and post-process, but obviously influenced by the different kinds of added material in swelling layer and the coating level of the inner swelling layer and the outer controlled layer. In vitro the lag time of release profile of VH from VH-COERP was 5 h and then VH was extended release from VH-COERP in the following time. Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.

CONCLUSIONThe release profile of VH from VH-COERP was shown to be extended-release after an conspicuous lag time in vitro and in vivo. So the drug can be taken by the patient before bed time and begin to work at the morning.

Administration, Oral ; Animals ; Biological Availability ; Calcium Channel Blockers ; administration & dosage ; pharmacokinetics ; Cellulose ; analogs & derivatives ; chemistry ; Delayed-Action Preparations ; Dogs ; Drug Stability ; Hypromellose Derivatives ; Methylcellulose ; analogs & derivatives ; chemistry ; Microscopy, Electron, Scanning ; Verapamil ; administration & dosage ; chemistry ; pharmacokinetics

AIMTo explore the appropriate dose of the verapamil and propranolol in kalium cardiaplegia (KVP) by observation of the effect on the function of ischemic immature rat heart and compared with ST. Thomas II cardiaplegia.

METHODS48 isolated hearts from Sprague-Dawley rats of 60 to approximately 80 g body weight, 22 +/- 2 days, male or female are perfused by Langendorff method for 20 min, and assigned to 1 of the following 6 groups (n = 8): control (CON), continuously perfused for 150 min. Ischemia/reperfusion (I/R), perfused with Locke's solution without glucose and oxygen equilibration for 3 min then no perfusion 27 min, repeated 3 cycles (ischemia for 90 min), followed by reperfusion for 60 min. Ischemia protected with ST. Thomas II cardioplegia (ST), each 3 min perfusion with ST. Thomas II cardioplegia during ischemia. Ischemia protected with three dose KVP cardioplegia (L, M, and H), perfused with ST. Thomas II cardioplegia containing verapamil and propranolol (x 10(-7) mol L(-1)) respectively 2.0, 0.34 (L), 6.8, 1.1 (M), 20,3.4 (H) during each 3 min perfusion of ischemia. Heart rate (min (-1), tens on(g), contraction force(g), peak systolic velocity (g.s-1), peak diastole velocity (g.s-), coronary flow (ml x min(-1 ), re-beat time (s) were monitored during the ischemia/ reperfusion.

RESULTSCompared to CON group, heart tension was rose when ischemia for 40 min and kept higher and could not rebeat after reperfusion in I/R group, In ST group, heart tension was rose after ischemia for 60 min and could re-beat but the pulse was weaker. Compared with ST group, KVP decreased the ischemic cardiac tension in dose dependently and the re-beat was stronger in L, M, and H groups. While compared with CON group, in L group, heart tension was rose when ischemia for 60 min and the re-beat was weaker. In H group, the heart tension was maintained lower when ischemia for 40 min and the re-beat was delay and weaker. Only in M group, heart tension was maintained stable during ischemia for 90 min and re-beat was stronger after reperfusion.

CONCLUSIONKalium cardiaplegia containing verapamil 6.8 x 10(-7) mol x L(-1) and propranolol 1.1 x 10(-7) mol x L(-1) has the best effect to protect the immature heart from ischemic injury.

Animals ; Cardioplegic Solutions ; administration & dosage ; pharmacology ; Female ; Heart ; drug effects ; In Vitro Techniques ; Male ; Myocardium ; metabolism ; Propranolol ; administration & dosage ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Reperfusion Injury ; prevention & control ; Verapamil ; administration & dosage ; pharmacology

AIMTo investigate the possible effect of tetramethylpyrazine (TMP), an active ingredient of a commonly used Chinese herb, on the pharmacokinetics of cyclosporine A (CsA) by intragastric administration in rats.

METHODSForty male Sprague-Dawley rats were equally divided into four groups by randomized block design according to weight. On the first day, after each fasting rat was intragastrically administered CsA (10 mg x kg(-1)), blood samples (0.2 - 0.25 mL) were collected from the tail vein at 0, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h. From day 4 to day 8, each group began to undergo different pretreatments with intragastric administration of water, verapamil (Ver), low and high dose TMP, separately. On day 9, each group intragastrically co-administered CsA (10 mg x kg(-1)) and different pretreatment compounds mentioned above, then blood samples were collected according to the schedule of the first day. The whole blood concentration of CsA was determined by HPLC. Main pharmacokinetic parameters were calculated and compared by statistic analysis.

RESULTSIn the group of water pretreated and co-administrated with CsA, no significantly different pharmacokinetic parameters of CsA were found. After Ver pretreatment and co-administration with CsA, AUC(0-48 h) and C(max) were increased significantly (P < 0.01 and P < 0.05); T(1/2) beta and CL were markedly prolonged and decreased (P < 0.05); T(max) and V were not apparently influenced. After low dose TMP pretreatment and co-administration with CsA, there was no significant difference in the pharmacokinetic parameters of CsA, in spite of the increasing trends of AUC(0-48 h) and C(max). After high dose TMP pretreatment and co-administration with CsA, AUC(0-48 h) and C(max) of CsA were increased significantly (P < 0.01), but there was no significant change in other parameters.

CONCLUSIONIt was indicated that the high dose of TMP could apparently increase the intragastric absorption extent of CsA, while almost had no effect on its elimination process.

Administration, Oral ; Animals ; Area Under Curve ; Biological Availability ; Calcium Channel Blockers ; pharmacology ; Cyclosporine ; administration & dosage ; blood ; pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Administration Routes ; Immunosuppressive Agents ; administration & dosage ; blood ; pharmacokinetics ; Ligusticum ; chemistry ; Male ; Plants, Medicinal ; chemistry ; Pyrazines ; administration & dosage ; isolation & purification ; pharmacology ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Stomach ; Verapamil ; pharmacology

To study the effects of major components of Maijunan tablets, puerarin (Pue) and rhynchophylline (Rhy) on the transport of hydrochlorothiazide (Hct) Caco-2 cell monolayer model, the transport parameters of Hct, such as apparent permeability coefficient (P(app) (B --> A) and P(app) (A --> B)) and the ratio of P(app) (B --> A) versus P(app) (A --> B), were studied and compared when Hct was used solely and co-used with Pue and/or Rhy. The effects of drug concentrations, conveying times, P-glyprotein (P-gp) inhibitor verapamil and conveying Liq pH values on the transport of Hct in the above conditions were also investigated. The results indicated that the absorption of Hct in Caco-2 cell monolayer model could be a carrier-mediated active transport, along with the excretion action mediated by P-gp. Pue can decrease the excretion action of Hct mediated by P-gp, and Rhy had no significant effect on the transport of Hct. The co-use of Hct, Pue and Rhy enhanced the absorption of Hct. Meanwhile, conveying Liq pH value had significant influence on the transport of Hct. The absorption of Hct at pH 6.0 was higher than that at pH 7.4.
ATP-Binding Cassette, Sub-Family B, Member 1 ; antagonists & inhibitors ; Absorption ; drug effects ; Biological Transport, Active ; drug effects ; Caco-2 Cells ; Drugs, Chinese Herbal ; administration & dosage ; isolation & purification ; pharmacology ; Humans ; Hydrochlorothiazide ; pharmacokinetics ; Hydrogen-Ion Concentration ; Indole Alkaloids ; administration & dosage ; isolation & purification ; pharmacology ; Isoflavones ; administration & dosage ; isolation & purification ; pharmacology ; Plants, Medicinal ; chemistry ; Time Factors ; Vasodilator Agents ; administration & dosage ; isolation & purification ; pharmacology ; Verapamil ; pharmacology

BACKGROUND: Dexmedetomidine is a highly selective alpha2-adrenoceptor agonist that is widely used for sedation and analgesia during the perioperative period. Intravenous administration of dexmedetomidine induces transient hypertension due to vasoconstriction via the activation of the alpha2-adrenoceptor on vascular smooth muscle. The goal of this in vitro study is to investigate the calcium-dependent mechanism underlying dexmedetomidine-induced contraction of isolated endothelium-denuded rat aorta. METHODS: Isolated endothelium-denuded rat thoracic aortic rings were suspended for isometric tension recording. Cumulative dexmedetomidine concentration-response curves were generated in the presence or absence of the following inhibitors: alpha2-adrenoceptor inhibitor rauwolscine; voltage-operated calcium channel blocker verapamil (5 x 10(-7), 10(-6) and 5 x 10(-5) M); purported inositol 1,4,5-trisphosphate receptor blocker 2-aminoethoxydiphenylborate (5 x 10(-6), 10(-5) and 5 x 10(-5) M); phospholipase C inhibitor U-73122 (10(-6) and 3 x 10(-6) M); and store-operated calcium channel inhibitor gadolinium chloride hexahydrate (Gd3+; 5 x 10(-6) M). Dexmedetomidine concentration-response curves were also generated in low calcium concentrations (1 mM) and calcium-free Krebs solution. RESULTS: Rauwolscine, verapamil, and 2-aminoethoxydiphenylborate attenuated dexmedetomidine-induced contraction in a concentration-dependent manner. Low calcium concentrations attenuated dexmedetomidine-induced contraction, and calcium-free Krebs solution nearly abolished dexmedetomidine-induced contraction. However, U-73122 and Gd3+ had no effect on dexmedetomidine-induced contraction. CONCLUSIONS: Taken together, these results suggest that dexmedetomidine-induced contraction is primarily dependent on extracellular calcium concentrations that contribute to calcium influx via voltage-operated calcium channels of isolated rat aortic smooth muscle. Dexmedetomidine-induced contraction is mediated by alpha2-adrenoceptor stimulation. Dexmedetomidine-induced contraction appears to be partially mediated by calcium release from the sarcoplasmic reticulum.
Administration, Intravenous ; Analgesia ; Animals ; Aorta ; Calcium ; Calcium Channels ; Contracts ; Dexmedetomidine ; Estrenes ; Gadolinium ; Hypertension ; Inositol 1,4,5-Trisphosphate ; Isotonic Solutions ; Muscle, Smooth ; Muscle, Smooth, Vascular ; Perioperative Period ; Pyrrolidinones ; Rats ; Sarcoplasmic Reticulum ; Type C Phospholipases ; Vasoconstriction ; Verapamil ; Yohimbine